Immunophotonics, Inc., a clinical-stage biotech company focused on developing novel Immune-stimulating drugs to augment routine tumor destruction techniques, has announced the appointment of Richard Levenson, M.D. to its Board of Directors.
Dr. Levenson further strengthens the company’s Board of Directors with his extensive expertise and track record as a scientist and thought leader. His appointment reflects Immunophotonics’ ongoing commitment to attract accomplished leaders who can shape and accelerate the company’s continued success. With his impressive credentials and experience in industry and academia, Dr. Levenson is expected to play a significant role in guiding the strategic direction and supporting the future growth of Immunophotonics.
Miguel Zubizarreta, CEO of Immunophotonics, commented, “We are pleased to welcome Dr. Levenson to our board and look forward to leveraging his expertise to further advance the company’s mission of transforming local tumor destruction treatments into systemic immuno-therapies. His deep expertise in pathology and imaging technologies, combined with his track record of innovation, will be invaluable as we advance our pipeline. Dr. Levenson’s insights will help guide our strategy and accelerate our progress toward delivering transformative cancer therapies to improve the lives of cancer patients.”
Read More: SalesTechStar Interview with Sahil Rekhi, Chief Revenue Officer at Graia
“I am honored to join the Immunophotonics Board of Directors as I believe the company’s pioneering approach of harnessing the immune system to prevent cancer recurrence following tumor ablation has the potential to transform the future of oncology and significantly improve patient outcomes. The convergence of immunology and technology is where the next great breakthroughs will emerge, and I am eager to help advance Immunophotonics’ bold vision,” remarked Dr. Levenson.
Dr. Levenson has 40+ years of experience in medical research, pathology, and advanced imaging technologies. He currently serves as Professor in the Department of Pathology & Laboratory Medicine at UC Davis Medical Center. His career spans academia, industry, and entrepreneurship, with significant contributions to multispectral imaging, quantitative pathology, and the development of innovative microscopy systems, including MUSE and FIBI, both now being commercialized. Dr. Levenson holds multiple patents and has been recognized with honors such as the UC Davis Chancellor’s Innovator of the Year award and election as a Fellow of SPIE.
Read More: Beyond CRM: How SalesTech is Shaping the Future of Deal Management?
